NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

NeoGenomics has announced the launch of its FDA-approved PTEN immunohistochemistry companion diagnostic test for prostate cancer, marking a significant milestone in the company's oncology diagnostics portfolio and reinforcing the growing role of companion diagnostics in guiding targeted therapy decisions for urologic malignancies.

The Technology

The newly launched assay uses immunohistochemistry to assess PTEN protein expression in tumor tissue from prostate cancer patients. PTEN, a tumor suppressor gene, is among the most frequently altered genes in prostate cancer, and its loss has been associated with more aggressive disease behavior and specific therapeutic vulnerabilities. As a companion diagnostic, the test is specifically designed and validated to identify patients whose tumors are most likely to respond to a paired therapeutic agent, moving the needle from broad prescribing to molecularly informed treatment decisions. IHC-based companion diagnostics offer laboratories a practical pathway to integrate biomarker testing into existing clinical workflows without requiring the infrastructure overhead of next-generation sequencing platforms, making adoption more accessible across a wider range of oncology laboratory settings.

Clinical Context

Prostate cancer remains one of the most commonly diagnosed malignancies among men globally, and the clinical management of advanced or metastatic disease has evolved substantially over the past decade. The identification of predictive biomarkers has become central to treatment stratification, particularly as the therapeutic landscape has expanded to include PARP inhibitors, androgen receptor pathway inhibitors, and other targeted agents. PTEN loss, detectable through IHC, has emerged as a clinically meaningful biomarker in this context, correlating with outcomes in patients receiving certain targeted therapies. The FDA approval of a companion diagnostic specifically tied to PTEN status in prostate cancer formalizes what has in some centers been an informal or research-use-only practice, bringing regulatory rigor and standardized interpretation criteria to a test that oncologists and pathologists can now confidently rely upon when making treatment recommendations.

Why This Matters

For clinical laboratories and diagnostic service providers, the launch of an FDA-approved companion diagnostic in a high-volume cancer type like prostate cancer represents a substantial commercial and clinical opportunity. Companion diagnostics carry reimbursement pathways that are more clearly defined than laboratory-developed tests, and the FDA imprimatur provides laboratories with the regulatory standing needed to incorporate the assay into standard of care workflows. NeoGenomics, as a specialized oncology testing organization, is well positioned to deploy this test at scale across its laboratory network, potentially accelerating patient access to biomarker-informed prostate cancer treatment. This development also signals continued momentum in the companion diagnostic segment as a whole, which is increasingly seen as a critical interface between molecular diagnostics and precision oncology therapeutics.

As regulatory agencies and payers continue to align reimbursement frameworks around validated companion diagnostics, approvals like this one are likely to drive broader laboratory investment in biomarker-specific assay development across solid tumor oncology.